Literature DB >> 25196028

Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells.

Nallely Jiménez-Mancilla1, Guillermina Ferro-Flores, Clara Santos-Cuevas, Blanca Ocampo-García, Myrna Luna-Gutiérrez, Erika Azorín-Vega, Keila Isaac-Olivé, Miguel Camacho-López, Eugenio Torres-García.   

Abstract

Radiolabeled gold nanoparticles may function simultaneously as radiotherapy and thermal ablation systems. The gastrin-releasing peptide receptor (GRP-r) is overexpressed in prostate cancer, and Lys(3) -bombesin is a peptide that binds with high affinity to the GRP-r. HIV Tat(49-57) is a cell-penetrating peptide that reaches the DNA. In cancer cells, (177) Lu shows efficient crossfire effect, whereas (99m) Tc that is internalized in the cancer cell nuclei acts as an effective system of targeted radiotherapy because of the biological Auger effect. The aim of this research was to evaluate the in vitro potential of (99m) Tc-labeled and (177) Lu-labeled gold nanoparticles conjugated to Tat(49-57)-Lys(3) -bombesin peptides ((99m) Tc/(177) Lu-AuNP-Tat-BN) as a plasmonic photothermal therapy and targeted radiotherapy system in PC3 prostate cancer cells. Peptides were conjugated to AuNPs (5 nm) by spontaneous reaction with the thiol group of cysteine (Cys). The effect on PC3 cell viability after laser heating of the AuNP-Tat-BN incubated with the cancer cells was conducted using an Nd:YAG laser pulsed for 5 ns at 532 nm (0.65 W/cm(2) ). For the (99m) Tc/(177) Lu-AuNP-Tat-BN to be obtained, the (177) Lu-DOTA-Gly-Gly-Cys and (99m) Tc-HYNIC-octreotide radiopeptides were first prepared and added simultaneously to a solution of AuNP-Tat-BN. (99m) Tc/(177) Lu-AuNP-Tat-BN (20 Bq/cell) was incubated with PC3 cells, and the effect on the cell proliferation was evaluated after 3 days. Fluorescence images of (99m) Tc/(177) Lu-AuNP-Tat-BN internalized in nuclei of PC3 were also obtained. After laser irradiation, the presence of AuNP-Tat-BN caused a significant increase in the temperature of the medium (46.4 vs 39.5 °C of that without AuNP) resulting in a significant decrease in PC3 cell viability down to 1.3%. After treatment with (99m) Tc/(177) Lu-AuNP-Tat-BN, the PC3 cell proliferation was inhibited. The nanosystem exhibited properties suitable for plasmonic photothermal therapy and targeted radiotherapy in the treatment of prostate cancer.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Lys3-bombesin; Tat peptide; gold nanoparticles; lutetium-177; nanoparticle-peptide; radiolabeled nanoparticles; radiolabeled peptides; technetium-99m

Mesh:

Substances:

Year:  2013        PMID: 25196028     DOI: 10.1002/jlcr.3087

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  20 in total

Review 1.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

2.  Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications.

Authors:  Zhengrong Guo; Huanyan Peng; Jiwen Kang; Dianxing Sun
Journal:  Biomed Rep       Date:  2016-03-23

Review 3.  Systematic imaging in medicine: a comprehensive review.

Authors:  Kai Zhang; Yujie Sun; Shuang Wu; Min Zhou; Xiaohui Zhang; Rui Zhou; Tingting Zhang; Yuanxue Gao; Ting Chen; Yao Chen; Xin Yao; Yasuyoshi Watanabe; Mei Tian; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-19       Impact factor: 9.236

Review 4.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

5.  Multimodal molecular 3D imaging for the tumoral volumetric distribution assessment of folate-based biosensors.

Authors:  Gerardo J Ramírez-Nava; Clara L Santos-Cuevas; Isaac Chairez; Liliana Aranda-Lara
Journal:  Med Biol Eng Comput       Date:  2017-12-01       Impact factor: 2.602

6.  Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.

Authors:  Brendan M Ottemann; Austin J Helmink; Wenting Zhang; Insiya Mukadam; Christopher Woldstad; James R Hilaire; Yutong Liu; JoEllyn M McMillan; Benson J Edagwa; R Lee Mosley; Jered C Garrison; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  Biomaterials       Date:  2018-09-14       Impact factor: 12.479

7.  Direct and Auger Electron-Induced, Single- and Double-Strand Breaks on Plasmid DNA Caused by 99mTc-Labeled Pyrene Derivatives and the Effect of Bonding Distance.

Authors:  Falco Reissig; Constantin Mamat; Joerg Steinbach; Hans-Juergen Pietzsch; Robert Freudenberg; Carlos Navarro-Retamal; Julio Caballero; Joerg Kotzerke; Gerd Wunderlich
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

Review 8.  Nuclear molecular imaging with nanoparticles: radiochemistry, applications and translation.

Authors:  D S Abou; J E Pickett; D L J Thorek
Journal:  Br J Radiol       Date:  2015-07-02       Impact factor: 3.039

9.  Fluorescent, Plasmonic, and Radiotherapeutic Properties of the 177Lu-Dendrimer-AuNP-Folate-Bombesin Nanoprobe Located Inside Cancer Cells.

Authors:  Héctor Mendoza-Nava; Guillermina Ferro-Flores; Flor de María Ramírez; Blanca Ocampo-García; Clara Santos-Cuevas; Erika Azorín-Vega; Nallely Jiménez-Mancilla; Myrna Luna-Gutiérrez; Keila Isaac-Olivé
Journal:  Mol Imaging       Date:  2017-01-01       Impact factor: 4.488

10.  GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI.

Authors:  Fan Pu; Jingjuan Qiao; Shenghui Xue; Hua Yang; Anvi Patel; Lixia Wei; Khan Hekmatyar; Mani Salarian; Hans E Grossniklaus; Zhi-Ren Liu; Jenny J Yang
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.